Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,447

Document Document Title
WO/2019/215317A1
The present invention relates to non-steroidal mineralocorticoid receptor antagonists (MR Antagonists, MRAs) alone or preferably in combination with sGC stimulators and/or sGC activators, for use in the prevention and/or treatment of mus...  
WO/2019/215470A1
The present invention relates to the use of Guanabenz or derivates thereof for the treatment of type I IFN-dependent pathologies.The inventors investigate here how pharmacological interference with the eIF2α-P pathway can be beneficial ...  
WO/2019/217757A1
The present disclosure relates to compounds and methods for modulating the expression ofc9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in whichc9orf72plays an active role. The compound can be a tran...  
WO/2019/215090A1
The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition...  
WO/2019/211734A1
The present invention relates to the field of adult stem cells of embryonic neural crest origin, in particular, multifunctional immature dental pulp stem cells (IDPSCs). The invention discloses useful compositions and methods for the pre...  
WO/2019/213442A1
In certain aspects, the disclosure provides multispecific binders (e.g., ΑctRΙΙΑ:ΤβRII heteromultimers comprising an ActRlIA polypeptide and a TfiRU polypeptide). The disclosure further provides that such multispecific binders (e.g...  
WO/2019/210552A1
Provided are a neutralizing antibody against tetanus toxins, and a use thereof. The provided neutralizing antibody against tetanus toxins is capable of specifically binding to tetanus toxins, and thus has strong neutralizing activity and...  
WO/2019/210347A1
A method of treating muscular dystrophy in a subject or for improving muscle function or delaying decline in muscle function in a subject with muscular dystrophy comprising administering to the subject a pharmaceutical composition compri...  
WO/2019/211399A1
The present invention concerns a composition in the form of a micro- emulsion composed of (i) an oil phase comprising at least one omega 3 fatty acid or salt thereof and at least one glyceride, (ii) an aqueous phase and (iii) one or more...  
WO/2019/210377A1
Two synthetic tetrapeptides having a high binding affinity to human muscular nicotinic acetylcholine receptor (HmnAChR) are provided. A composition for inhibiting contraction of muscle cells is also provided. The composition comprises an...  
WO/2019/208627A1
The purpose of the present invention is to provide a composition, which comprises as an active ingredient a substance having an effect of preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle ma...  
WO/2019/205700A1
Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual admin...  
WO/2019/208968A1
The present invention relates to a pharmaceutical composition comprising dimenhydrinate, harmol, and/or calcium pantothenate for preventing or treating a muscular disease, wherein dimenhydrinate, harmol, and/or calcium pantothenate each ...  
WO/2019/205959A1
Disclosed are a pharmaceutical composition for treating epilepsy and convulsions, infantile convulsions and facial spasms and a preparation method therefor. The pharmaceutical composition comprises extracts of medicinal materials and aux...  
WO/2019/208812A1
A compound represented by general formula (1), a salt thereof, or a prodrug thereof is provided as a compound effective in the prevention and/or treatment of fibrosis. (In the formula, A is an optionally substituted benzene ring; B is an...  
WO/2019/202162A1
The present invention relates to agents capable to inhibit miR-181, for use in treatment and/or prevention of mitochondrial disorders including mitochondrial diseases with eye and/or brain involvement and neurodegeneration affecting eye ...  
WO/2019/203296A1
A preventative and/or therapeutic agent for sarcopenia having as an active ingredient a prostaglandin D2 production inhibitor.  
WO/2019/200161A1
The present disclosure relates to compounds and methods which may be useful for modulating the expression of cnbp and treating diseases and conditions in which cnbp plays an active role.  
WO/2018/136943A9
Described herein are compositions comprising activators of TRP and ASIC channels that may be useful to improve or preserve exercise performance and exercise recovery.  
WO/2019/195304A1
The present disclosure relates to mir-17~92 as a candidate therapeutic or diagnostic target of motor neuron (MN) degeneration diseases. Expression of mir-17~92 is sustained throughout adulthood in spinal MNs and specifically decreases be...  
WO/2019/194217A1
A monoclonal antibody produced by an established hybridoma expresses high selectivity for IL-18, and is also capable of performing western blotting, immunoprecipitation and immunostaining that are important for analyzing functions of IL-...  
WO/2019/191204A1
The disclosure provides methods of treating a subject having a disease or disorder associated with muscle contractures by administering a follistatin polypeptide, wherein the polypeptide includes truncated variants of follistatin, as wel...  
WO/2019/190175A2
The present invention relates to a method for differentiating motor neurons from tonsil-derived mesenchymal stem cells, and a cell therapy agent using same. The differentiation method of the present invention exhibits high differentiatio...  
WO/2019/188491A1
The present invention addresses the problem of providing a novel anti-aging composition. A means for solving the problem is to use at least one compound selected from the group consisting of a lophenol compound and a cyclolanostane compo...  
WO/2019/186171A1
The present invention relates to an inhibitor of HSD11B1, or a pharmaceutical formulation thereof in association with a pharmaceutically acceptable carrier therefor, for use in the treatment, prevention or amelioration of sarcopenia or a...  
WO/2019/184773A1
The present invention discloses a method for removing gas-phase impurities in Sugammadex sodium. The method comprises steps such as water dissolvation, distillation, drying and the like in mild conditions, and is suitable for mass produc...  
WO/2018/169804A8
A neuromuscular toxin is for use in treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal by administering an amount of neuromuscular toxin effective to treat the abnormalities via intramuscular injection ...  
WO/2019/180269A1
The present invention relates to ALK5 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a diseas...  
WO/2019/183536A1
Methods and systems for treating spasticity, hypertonia or dystonia are disclosed.  
WO/2019/178759A1
Disclosed is a composition for promoting local muscle growth or slowing down or preventing local muscle atrophy, which composition contains a polypeptide in the C2 region of the enterotoxin Staphylococcus aureus and a myostatin polypepti...  
WO/2019/179361A1
Provided is a composition for improving sphincter insufficiency, comprising a substrate additive and a recombinant protein. The composition is used to achieve the effect of reducing sphincter atrophy, promoting sphincter growth and sphin...  
WO/2019/182109A1
The present invention addresses the problem of providing a nucleic acid agent and a composition including the same, said nucleic acid agent having an antisense effect on a target transcriptional product at the site of delivery and being ...  
WO/2019/176864A1
An agent for the treatment or prevention of muscular-dystrophy-related cardiomyopathy, the agent containing as an active ingredient a compound represented by formula (1) or a phamacologically acceptable salt or solvate thereof. [In formu...  
WO/2019/176693A1
Provided is an inhibitor of the expression of a bone formation-related factor or a calcification-related factor in an extraskeletal tissue. An inhibitor of the expression of a bone formation-related factor in an extraskeletal tissue, the...  
WO/2019/177135A1
The purpose of the present invention is to provide a method for producing a uniform and homogeneous sheet-shaped cell culture, in which dissemination is carried out while a portion of a discharge tool is in contact with a culture base ma...  
WO/2019/177071A1
[Problem] To provide a food product which enables training of tongue muscles regardless of place and time, and a method for using the same. [Solution] This tongue muscle training food product comprises a sheet-shaped food product formed ...  
WO/2019/177313A1
The present invention relates to a dual functional peptide having a cell permeation ability and a muscle regeneration ability, and a use thereof. A dual functional peptide according to the present invention has the ability to regenerate ...  
WO/2019/175278A1
The invention relates to a modulator of small conductance calcium activated K+ channels of the vestibular nuclei cells for use in the treatment of a lesional vestibular disorder in a patient in need thereof, and to a pharmaceutical compo...  
WO/2019/177163A1
This application provides: a novel mouse artificial chromosome vector that is stable in rodent cells or tissues or rodent individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from the gr...  
WO/2019/178613A1
The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as follistatin. Specifically disclosed are methods for administering a single, maxi...  
WO/2019/166347A1
The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility ...  
WO/2019/167178A1
This method for analyzing the phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug involves: obtaining a first measured value by measuring the phenylhydrazine content of a standard solution that contains phenylhydra...  
WO/2019/167974A1
This method for analyzing the phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug involves: obtaining a first measured value by measuring the phenylhydrazine content of a standard solution that contains phenylhydra...  
WO/2019/169283A1
The present invention relates to compositions and methods for altering body composition in a subject, wherein the alteration of body composition is an increase in muscle mass and a reduction of fat mass simultaneously. The present invent...  
WO/2019/168985A1
A composition comprising a small molecule therapeutic agent and an organic acid compound is described. The small molecule therapeutic agent (i) has a water solubility at room temperature of less than about 1.0 g/L and (ii) is a base. The...  
WO/2019/166717A1
The invention concerns a composition comprising at least one phytoecdysone or at least one semi-synthetic derivative of a phytoecdysone, for use in mammals for preventing the loss of muscle strength during immobilisation. More particular...  
WO/2019/164597A1
The present invention includes methods and compositions for treating a skeletal muscular atrophy caused by a defect in the function of one or more sarco/endoplasmic reticulum Ca2+- ATPase (SERCA) pumps comprising: identifying a subject h...  
WO/2019/164852A1
Disclosed herein are methods and compositions for the treatment of movement disorders including neuromuscular disorders, muscular injuries, and spasticity-associated conditions. Methods of treatment include reducing skeletal muscle contr...  
WO/2019/165313A1
Plantar Heel Pain Syndrome can be of one or more etiologies and symptoms which refutes the mistaken tendency to categorize all plantar heel pain singularly as either plantar fasciitis or fasciosis. Recognizing that there is likely an int...  
WO/2019/163917A1
Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as...  

Matches 1 - 50 out of 25,447